When.com Web Search

  1. Ads

    related to: carboplatin and docetaxel for breast cancer risk assessment printable

Search results

  1. Results From The WOW.Com Content Network
  2. TCH (chemotherapy) - Wikipedia

    en.wikipedia.org/wiki/TCH_(chemotherapy)

    TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References [ edit ]

  3. Chemotherapy regimen - Wikipedia

    en.wikipedia.org/wiki/Chemotherapy_regimen

    breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor TCHP

  4. Docetaxel - Wikipedia

    en.wikipedia.org/wiki/Docetaxel

    Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]

  5. What's your breast cancer risk? Here's how to use assessment ...

    www.aol.com/lifestyle/whats-breast-cancer-risk...

    Searches for breast cancer risk assessment tools like the one Munn used spiked as well. In a post she shared on Instagram, Munn urged all women to ask their health care providers to calculate ...

  6. What to Know About the Breast Cancer Risk Assessment ... - AOL

    www.aol.com/know-breast-cancer-risk-assessment...

    The Breast Cancer Risk Assessment Tool (BCRAT), also known as the Gail Model, is one of the most common and popular tests used to identify those women at risk for breast cancer, says Sherry Ross ...

  7. Breast cancer chemotherapy - Wikipedia

    en.wikipedia.org/wiki/Breast_cancer_chemotherapy

    By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines.

  1. Ads

    related to: carboplatin and docetaxel for breast cancer risk assessment printable